Diamyd Medical AB: New Study Application to Vaccinate Against Juvenile Diabetes with Diamyd(R)

STOCKHOLM, Sweden--(BUSINESS WIRE)-- Regulatory News: Diamyd Medical AB (publ.) (Pink Sheets:DMYDY) (STO:DIAMB): A renowned research group at Lund University has filed an application with the Swedish Medical Products Agency to carry out a study of the diabetes vaccine Diamyd® for the prevention of type 1 diabetes in Swedish children. This is the second prevention study with the diabetes vaccine Diamyd® for which approval has been sought in a short period.